Irritable Bowel Syndrome (IBS) Treatment in Dallas & Sachse, TX

What Is Irritable Bowel Syndrome (IBS)?

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits — including diarrhea, constipation, or both — in the absence of any identifiable structural or biochemical abnormality. It is one of the most common conditions diagnosed by gastroenterologists worldwide, affecting an estimated 10 to 15 percent of the global population and approximately 25 to 45 million people in the United States alone, according to the American College of Gastroenterology (ACG).

Unlike inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, IBS does not cause visible inflammation, ulcers, or permanent damage to the digestive tract. Instead, it is classified as a disorder of gut-brain interaction (DGBI), meaning the symptoms arise from abnormal communication between the brain and the gastrointestinal system rather than from structural disease. Despite the absence of visible damage, IBS symptoms are real, often disabling, and can significantly reduce a patient's quality of life.

The diagnosis of IBS is made using the Rome IV criteria, the current international standard for diagnosing functional gastrointestinal disorders. Under these criteria, IBS is defined as recurrent abdominal pain occurring on average at least one day per week during the preceding three months, associated with two or more of the following: the pain is related to defecation, it is associated with a change in the frequency of stool, or it is associated with a change in the form (appearance) of stool. These criteria must be met with symptom onset at least six months before diagnosis.

At Texas Gut Health in Sachse, TX, Dr. Jaison John provides comprehensive, evidence-based IBS care for patients throughout the Dallas-Fort Worth area. Dr. John completed his gastroenterology fellowship at UT Medical Branch, where he served as Chief Fellow, and his internal medicine residency at UT Austin Dell Medical School, where he served as Chief Resident. He holds dual board certifications from the American Board of Internal Medicine in both internal medicine and gastroenterology, ensuring that every patient receives expert-level evaluation and a personalized treatment plan grounded in the latest ACG and American Gastroenterological Association (AGA) guidelines.

Types of IBS

IBS is classified into four subtypes based on the predominant stool pattern, as defined by the Rome IV criteria. Identifying your specific subtype is essential because treatment approaches, including dietary recommendations and medications, differ depending on whether constipation, diarrhea, or a mixed pattern predominates.

• IBS-C (IBS with predominant constipation) — More than 25 percent of bowel movements are hard or lumpy (Bristol Stool Form Scale types 1 or 2), and fewer than 25 percent are loose or watery. Patients with IBS-C often experience infrequent stools, straining, a sensation of incomplete evacuation, and abdominal bloating. This subtype is more common in women and may respond to fiber supplementation, osmotic laxatives, or prescription medications such as linaclotide or lubiprostone.
• IBS-D (IBS with predominant diarrhea) — More than 25 percent of bowel movements are loose or watery (Bristol Stool Form Scale types 6 or 7), and fewer than 25 percent are hard or lumpy. Patients with IBS-D frequently report urgency, frequent bowel movements, and anxiety about access to restrooms. Treatment options may include dietary changes, loperamide for symptom relief, bile acid sequestrants, or the antibiotic rifaximin.
• IBS-M (IBS with mixed bowel habits) — More than 25 percent of bowel movements are hard or lumpy, and more than 25 percent are loose or watery. Patients with IBS-M alternate between constipation and diarrhea, sometimes within the same day or week. This subtype can be the most challenging to manage because therapies that improve one symptom may worsen the other. Treatment requires careful individualization.
• IBS-U (IBS unsubtyped) — Patients meet the diagnostic criteria for IBS but their stool pattern does not fit neatly into the constipation-predominant, diarrhea-predominant, or mixed categories. IBS-U is less common and is managed based on the individual's most bothersome symptoms.

Dr. John determines your IBS subtype during your initial evaluation at our Sachse office, using a combination of your symptom history, stool diaries, and the Bristol Stool Form Scale. This classification guides every aspect of your treatment plan.

Symptoms of IBS

The hallmark symptoms of IBS include abdominal pain, bloating, and changes in bowel habits. However, symptoms vary widely among patients, and the pattern and severity can fluctuate over time. The following are the most commonly reported symptoms of irritable bowel syndrome:

• Abdominal pain and cramping — The defining symptom of IBS. The pain is typically located in the lower abdomen, though it can occur anywhere in the abdominal region. A key characteristic of IBS-related pain is its relationship to bowel movements: pain may improve or worsen with defecation. The pain is often described as cramping, aching, or sharp and tends to come and go rather than remain constant.
• Bloating and abdominal distension — Many IBS patients report a sensation of fullness, tightness, or swelling in the abdomen. Visible abdominal distension — a measurable increase in abdominal girth — may also occur. Bloating is one of the most bothersome symptoms for patients and is often worse after meals or later in the day.
• Diarrhea — Frequent, loose, or watery stools, often accompanied by urgency (a sudden, strong need to have a bowel movement). Patients with IBS-D may have three or more loose stools per day, and episodes may be triggered by meals, stress, or specific foods.
• Constipation — Infrequent bowel movements (fewer than three per week), hard or lumpy stools, straining during defecation, and a sensation of incomplete evacuation. Patients with IBS-C may go several days without a bowel movement and often feel that their bowels have not emptied fully even after passing stool.
• Alternating bowel habits — Some patients experience unpredictable swings between diarrhea and constipation over days, weeks, or months.
• Mucus in stool — Passage of white or clear mucus with bowel movements is common in IBS and, in the absence of other alarm symptoms, is generally not a sign of a more serious condition.
• Gas and flatulence — Increased intestinal gas production and passage of gas are frequently reported and may be related to dietary factors and alterations in the gut microbiome.

IBS symptoms often overlap with other gastrointestinal conditions, including celiac disease, inflammatory bowel disease, and functional dyspepsia. For this reason, a thorough evaluation by a board-certified gastroenterologist is essential to arrive at the correct diagnosis and rule out other conditions that may require different treatment.

Causes and Risk Factors

The exact cause of IBS is not fully understood, but decades of research have identified several interacting factors that contribute to the development and persistence of symptoms. IBS is now recognized as a multifactorial disorder involving the gut-brain axis, the gut microbiome, immune activation, and psychological factors. Understanding these mechanisms helps explain why IBS affects each patient differently and why treatment must be individualized.

Gut-Brain Axis Dysfunction

The gut-brain axis is a bidirectional communication network that connects the central nervous system (brain and spinal cord) with the enteric nervous system (the network of nerves that governs the gastrointestinal tract). In patients with IBS, this communication system is dysregulated, leading to abnormal processing of signals between the gut and the brain. This dysfunction can amplify pain perception, alter gut motility, and contribute to the emotional distress that frequently accompanies IBS.

Visceral Hypersensitivity

Many patients with IBS have heightened sensitivity to normal sensations in the gut, a phenomenon known as visceral hypersensitivity. Activities that would not cause discomfort in a healthy individual — such as normal gas distension or regular peristaltic contractions — are perceived as painful in IBS patients. Research published in the journal Gastroenterology has shown that up to 60 percent of IBS patients demonstrate visceral hypersensitivity on balloon distension testing.

Altered Gut Motility

The speed at which food and waste move through the digestive tract is often abnormal in IBS. In patients with IBS-D, intestinal transit may be too fast, resulting in loose stools and urgency. In patients with IBS-C, transit may be too slow, leading to hard stools and infrequent bowel movements. These motility disturbances are influenced by the enteric nervous system, hormones, dietary factors, and stress.

Post-Infectious IBS

Approximately 10 to 15 percent of IBS cases develop after an acute gastrointestinal infection, such as bacterial gastroenteritis caused by Salmonella, Campylobacter, or E. coli. This is known as post-infectious IBS (PI-IBS). The infection may trigger persistent changes in the gut microbiome, low-grade immune activation, and increased intestinal permeability that sustain IBS symptoms long after the original infection has resolved. PI-IBS is more commonly associated with IBS-D.

Gut Microbiome Alterations

The gut microbiome — the trillions of bacteria, fungi, and other microorganisms residing in the intestinal tract — plays a critical role in digestion, immune function, and gut-brain communication. Studies have consistently shown that patients with IBS have an altered composition and diversity of gut bacteria compared to healthy individuals. These microbial changes may contribute to gas production, bloating, altered motility, and visceral hypersensitivity. This understanding has led to the investigation of microbiome-targeted therapies, including probiotics and the antibiotic rifaximin, for IBS management.

Psychological Factors and Stress

Psychological conditions including anxiety, depression, and a history of trauma are significantly more prevalent in patients with IBS than in the general population. Stress is a well-established trigger for IBS flares, acting through the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system to alter gut motility, increase visceral sensitivity, and promote intestinal inflammation. Notably, the relationship between psychological factors and IBS is bidirectional: having IBS can cause or worsen anxiety and depression, and these psychological states can in turn intensify GI symptoms.

Other Risk Factors

• Sex — IBS is approximately 1.5 to 2 times more common in women than men. Hormonal fluctuations during the menstrual cycle may influence symptom severity.
• Age — IBS most commonly develops before age 50, with many patients experiencing their first symptoms in their teens, twenties, or thirties.
• Diet — Certain foods, particularly those high in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols), can trigger or exacerbate IBS symptoms by increasing gas production and drawing water into the intestinal lumen.
• Genetics — Family studies suggest a modest genetic component to IBS, with first-degree relatives of IBS patients being at higher risk of developing the condition.

How IBS Is Diagnosed

IBS is a clinical diagnosis, meaning it is made based on your symptoms and medical history rather than on a single definitive test. The current diagnostic standard is the Rome IV criteria, which were developed by an international panel of gastroenterology experts and are endorsed by the ACG and AGA.

The Rome IV Diagnostic Criteria

To meet the Rome IV criteria for IBS, a patient must have recurrent abdominal pain on average at least one day per week in the last three months, with symptom onset at least six months before diagnosis. The pain must be associated with at least two of the following three features:

• The pain is related to defecation (either improves or worsens)
• The pain is associated with a change in the frequency of stool
• The pain is associated with a change in the form (appearance) of stool

When these criteria are met and no alarm symptoms are present, IBS can be diagnosed with confidence using a positive diagnostic strategy — meaning the diagnosis is made based on the presence of characteristic symptoms rather than by exhaustively ruling out every other possible condition. The ACG guidelines emphasize that a positive diagnostic approach reduces unnecessary testing, lowers healthcare costs, and does not increase the risk of missing a serious diagnosis.

Limited Diagnostic Testing

While extensive testing is not necessary for most IBS patients, your gastroenterologist may recommend a limited set of tests to rule out conditions that can mimic IBS:

• Complete blood count (CBC) — To screen for anemia or infection.
• C-reactive protein (CRP) or fecal calprotectin — Inflammatory markers that help distinguish IBS from inflammatory bowel disease. Normal levels strongly support a diagnosis of IBS over IBD.
• Celiac disease screening — The ACG recommends serologic testing for celiac disease (tissue transglutaminase IgA antibody) in all patients presenting with IBS-D or IBS-M symptoms, as celiac disease affects approximately 1 percent of the population and can present with symptoms identical to IBS.
• Thyroid function tests — Hypothyroidism can cause constipation, and hyperthyroidism can cause diarrhea, both of which may mimic IBS.

When a Colonoscopy Is Needed

A colonoscopy is not required for the diagnosis of IBS in most patients. However, Dr. John may recommend a colonoscopy in the following circumstances:

• You are age 45 or older and are due for routine colorectal cancer screening
• You have alarm symptoms such as rectal bleeding, unintended weight loss, or iron-deficiency anemia
• You have a family history of colorectal cancer or inflammatory bowel disease
• Your symptoms do not respond to initial treatment, and other diagnoses need to be excluded
• Microscopic colitis is suspected, as this condition can only be diagnosed by biopsy obtained during colonoscopy

In some cases, an upper endoscopy (EGD) may also be performed to evaluate for celiac disease, especially if serologic testing is positive or equivocal, or if upper GI symptoms such as nausea or early satiety are prominent.

Treatment Options for IBS

Effective IBS management requires a multifaceted, individualized approach that addresses dietary triggers, gut motility, visceral sensitivity, and the psychological components of the condition. At Texas Gut Health, Dr. John develops a personalized treatment plan for each patient based on their specific IBS subtype, symptom severity, and treatment goals. The following are the primary evidence-based treatment categories, consistent with current ACG and AGA guidelines.

Dietary Modifications

Diet is one of the most powerful tools for managing IBS symptoms, and for many patients, dietary changes alone provide meaningful relief.

• Low-FODMAP diet — The low-FODMAP diet is the most extensively studied dietary intervention for IBS. Developed by researchers at Monash University, it involves a structured three-phase approach: elimination of high-FODMAP foods for two to six weeks, systematic reintroduction of individual FODMAP groups to identify personal triggers, and long-term personalization of the diet based on tolerance. Clinical trials have shown that the low-FODMAP diet reduces overall IBS symptoms in 50 to 80 percent of patients. High-FODMAP foods include onions, garlic, wheat, certain fruits (apples, pears, mangoes, watermelon), lactose-containing dairy products, legumes, and artificial sweeteners such as sorbitol and mannitol.
• Fiber modification — Soluble fiber supplements such as psyllium (Metamucil) have been shown to improve overall IBS symptoms, particularly in patients with IBS-C. The ACG recommends soluble fiber over insoluble fiber (such as wheat bran), which may worsen bloating and pain in some IBS patients. Fiber should be introduced gradually to minimize gas and bloating.
• Identifying individual triggers — Beyond the low-FODMAP diet, patients may benefit from keeping a food and symptom diary to identify specific personal triggers such as caffeine, alcohol, fatty foods, or spicy foods.

Medications

When dietary changes alone are insufficient, several categories of medications can help manage IBS symptoms. The choice of medication depends on the predominant symptom pattern and IBS subtype.

• Antispasmodics — Medications such as hyoscyamine and dicyclomine relax the smooth muscle of the intestinal wall, reducing cramping and abdominal pain. They are most effective when taken before meals or during symptom flares. The ACG recommends antispasmodics for short-term relief of abdominal pain in IBS.
• Peppermint oil — Enteric-coated peppermint oil capsules have demonstrated efficacy in multiple clinical trials for reducing IBS-related abdominal pain and bloating. The ACG recommends peppermint oil as a first-line therapy for overall IBS symptom improvement.
• Neuromodulators (gut-brain therapies) — Tricyclic antidepressants (TCAs) such as amitriptyline or nortriptyline, used at low doses, can reduce visceral pain and slow gut transit, making them particularly useful for IBS-D. Selective serotonin reuptake inhibitors (SSRIs) may benefit patients with coexisting anxiety or depression. These medications work by modulating the gut-brain axis and are not prescribed for depression in this context but specifically for their effect on gut pain signaling.
• Rifaximin — This non-absorbable antibiotic has been approved by the FDA for the treatment of IBS-D. It works by altering the composition of the gut microbiome and reducing bacterial overgrowth. Clinical trials have shown that a 14-day course of rifaximin provides sustained symptom relief in a significant proportion of IBS-D patients, and retreatment is effective if symptoms recur.
• Medications for IBS-C — Prescription options for constipation-predominant IBS include linaclotide (Linzess), lubiprostone (Amitiza), and plecanatide (Trulance). These medications increase fluid secretion into the intestine, soften stool, and may also reduce abdominal pain.
• Medications for IBS-D — In addition to rifaximin, loperamide (Imodium) can be used for short-term relief of diarrhea. Eluxadoline (Viberzi) is a prescription medication that acts on opioid receptors in the gut to reduce bowel contractions and diarrhea. Bile acid sequestrants such as cholestyramine may be helpful if bile acid malabsorption is contributing to diarrhea.

Lifestyle and Behavioral Therapies

Given the central role of the gut-brain axis in IBS, behavioral and lifestyle interventions are an important component of comprehensive treatment.

• Cognitive behavioral therapy (CBT) — CBT is the most extensively studied psychological therapy for IBS and has been shown in randomized controlled trials to reduce IBS symptom severity by 50 to 70 percent. CBT helps patients identify and modify thought patterns and behaviors that contribute to symptom amplification and avoidance behaviors.
• Gut-directed hypnotherapy — This specialized form of hypnotherapy, developed at the University of Manchester, uses guided relaxation and suggestion to reduce visceral sensitivity and improve gut function. Multiple clinical trials have demonstrated its efficacy, and it is recommended by the ACG as an effective therapy for overall IBS symptoms.
• Regular physical activity — Moderate exercise, such as 20 to 30 minutes of walking, cycling, or swimming most days of the week, has been shown to improve IBS symptoms, reduce stress, and promote regular bowel function.
• Stress management — Mindfulness meditation, yoga, deep breathing exercises, and progressive muscle relaxation can help reduce the stress response that triggers IBS flares.
• Sleep hygiene — Poor sleep quality is common in IBS patients and can worsen symptoms. Maintaining a regular sleep schedule, limiting screen time before bed, and addressing sleep disorders can support overall GI health.

Probiotics

Probiotics — live beneficial bacteria taken as supplements or in fermented foods — have shown promise for reducing specific IBS symptoms, particularly bloating and flatulence. However, the evidence is mixed, and the optimal strain, dose, and duration of probiotic therapy for IBS have not been definitively established. The AGA conditionally recommends against the use of probiotics for IBS outside of clinical trials, though individual patients may experience benefit. Dr. John can help you evaluate whether a specific probiotic formulation may be appropriate for your situation.

Living with IBS

IBS is a chronic condition that requires long-term management, but with the right treatment strategy, the vast majority of patients can achieve significant symptom relief and maintain a high quality of life. Living well with IBS involves ongoing collaboration between you and your gastroenterologist to adapt your treatment plan as your symptoms and circumstances change over time.

Long-Term Dietary Management

After completing the elimination phase of the low-FODMAP diet, most patients can reintroduce many foods and follow a modified, less restrictive diet that avoids only their personal triggers. The goal is not lifelong restriction but rather informed, personalized eating. Regular follow-up with Dr. John can help ensure your diet remains nutritionally balanced while effectively managing symptoms. For patients in the Dallas-Fort Worth area, our office can also coordinate with registered dietitians who specialize in gastrointestinal nutrition.

The Mental Health Connection

The bidirectional relationship between mental health and IBS cannot be overstated. Anxiety about symptoms can lead to food avoidance, social isolation, and hypervigilance about bodily sensations, all of which can paradoxically worsen IBS. Conversely, effective treatment of IBS symptoms often leads to significant improvements in mood and anxiety. If you are experiencing anxiety, depression, or significant stress in connection with your IBS, discussing this openly with Dr. John is an important step. He can recommend evidence-based psychological therapies, coordinate with mental health professionals, or adjust your medication regimen to address both the gut and brain components of the condition.

Follow-Up and Monitoring

IBS symptoms may fluctuate over months and years, and your treatment plan should evolve accordingly. Regular follow-up appointments allow Dr. John to assess your response to treatment, adjust medications, introduce new therapies, and screen for any changes in your symptoms that might warrant additional testing. Patients in Sachse, Murphy, Wylie, Plano, Garland, Rowlett, Richardson, and throughout the DFW metroplex can conveniently access ongoing care at our office located at 4650 President George Bush Hwy, Suite 210, Sachse, TX 75048.

Support and Education

Understanding your condition is one of the most empowering steps you can take. Knowing that IBS is a real, medically recognized disorder — not something that is "all in your head" — and that effective treatments exist can reduce the fear and frustration that often accompany the diagnosis. National organizations such as the International Foundation for Gastrointestinal Disorders (IFFGD) and the ACG provide reliable, patient-friendly educational resources about IBS.

Frequently Asked Questions